The European Patent Office (EPO) has issued a “notice of intent” to grant…
Articles by Ana Pena, PhD
Female sex, younger age, and a better lung function at time of diagnosis tend to support a a…
Overactivation of a protein called mucin 1 (MUC1) triggers pro-fibrotic transformations in the lungs that could contribute to the…
miRagen Therapeutics is reshaping its strategy to focus on the development of MRG-229, a potential…
Enrollment in the Phase 2 clinical trial of setanaxib (GKT831), an oral investigational treatment for idiopathic pulmonary fibrosis…
A metabolic process called the mevalonate pathway may be a promising therapeutic target to fight idiopathic pulmonary fibrosis…
MUC5B genetic variants and shorter telomeres — or chromosome endings — are risk factors associated with greater lung…
A genetic variant at the IFNL3 gene is linked to raised levels of IFN-lambda 3 in the blood and is…
Veracyte announced new data further supporting its Envisia Genomic Classifier as…
Healthy and idiopathic pulmonary fibrosis (IPF) lung cells respond differently to transforming growth factor-beta 1 (TGF-beta 1) —…